Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797376 | 1.00 | USP2 (0.50) | USP2SLCO1B1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL4957561 | 1.00 | USP2 (0.50) | USP2SLCO1B1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL23200783 | 1.00 | USP2 (0.50) | USP2SLCO1B1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL757841 | 0.79 | — | — | |
| SCHEMBL3798816 | 0.79 | — | — | |
| SCHEMBL8055114 | 0.77 | USP2 (0.54) | USP2SLCO1B1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL27788890 | 0.77 | — | — | |
| SCHEMBL27332107 | 0.77 | — | — | |
| SCHEMBL497584 | 0.74 | USP2 (0.52) | USP2SLCO1B1SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL29057555 | 0.74 | SLC7A5 (0.46) | USP2SLCO1B1SLC7A5SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785825-B2 | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-08-31 | — | — | US | disclosed |
| US-20050164339-A1 | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164339-A1 | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics | VIP, PTMS, NRDC | USP2 4225/4885SLCO1B1 4577/4885SLC7A5 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.